Folic acid prevents the initial occurrence of sporadic colorectal adenoma in Chinese over 50 years of age: a randomized clinical trial

Qin-Yan Gao1*, Hui-Min Chen1*, Ying-Xuan Chen1, Ying-Chao Wang1, Zheng-Hua Wang1, Jie-Ting Tang1, Zhi-Zheng Ge1, Xiao-Yu Chen1, Jian-Qiu Sheng2, Dian-Chun Fang3, Cheng-Gong Yu4, Ping Zheng5, Jing-Yuan Fang1#

* The two authors contributed equally to this work.

#Correspondence to: Jing-Yuan Fang, M.D., Ph.D.

Email: jingyuanfang@yahoo.com

Renji Hospital, Shanghai Jiao-Tong University School of Medicine
145 Shandong Rd Middle. Shanghai 200001, China
Tel: +86-21-53882450, Fax: +86-21-63266027

1 Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease. Key Laboratory of Gastroenterology & Hepatology, Ministry of Health; State Key Laboratory of Oncogene and Related Genes, 145 Middle Shandong Rd, Shanghai 200001, China.

2 Division of Gastroenterology, PLA. The Military General Hospital of Beijing,

3 Division of Gastroenterology and Hepatology, Southwest Hospital, Third Military Medical University.
Running title:
Folic acid prevent the initial of colorectal adenoma in age>50

This work was supported by the grants from the National Science Found of China (30830055) and the Ministry of Public Health, China (No. 200802094).

The Corresponding Author has the right to grant on behalf of all authors.

All authors of this manuscript have read and approved the final manuscript, and declared no conflict of interest

Word count: 4012

Total number of figures and tables: 1 figures and 4 tables
Abstract

Colorectal adenoma (CRA) is the precursor lesion of colorectal cancer (CRC). Several agents have been shown to be effective in the chemoprevention of CRA recurrence, but there has been little research on its primary prevention. Participants aged ≥50 years with no adenomas were recruited for our study and randomized to receive either 1 mg/d FA supplement or treatment without FA. After 3 years of follow-up, plasma folate and colonoscopy were evaluated. Seven-hundred and ninety-one participants (91.98%) completed the study. CRA occurred in 64 (14.88%) participants in the FA group and 132 (30.70%) in the control group (unadjusted RR, 0.49; 95% CI: 0.37–0.63; \(P<0.01\)); left-sided adenoma (unadjusted RR, 0.54; 95% CI: 0.38–0.76; \(P=0.001\)) and advanced CRA (unadjusted RR, 0.36; 95% CI: 0.16–0.81; \(P=0.01\)) were most common. There was no significance difference in the occurrence of three or more adenomas (unadjusted RR, 0.70; 95% CI: 0.36–1.77; \(P=0.38\)) or right-sided adenoma (unadjusted RR, 0.55; 95% CI: 0.30–1.00; \(P=0.07\)) between the two groups. Participants with low plasma folate may have a high risk of CRA. In conclusion, primary prevention with 1mg/d FA supplementation could reduce the incidence of CRA, especially left-sided and advanced disease in those with no previous adenomas. People with differing baseline plasma folate levels should be given individualized treatment. Those with low plasma folate should be encouraged to take adequate supplements; plasma folate should be elevated to an effective therapeutic level, which may reduce the incidence of CRA.

Keywords: Colorectal adenoma; folic acid; primary prevention.
Introduction

Almost 90% of cases of colorectal cancer (CRC) develop from colorectal adenoma (CRA) (1-4). CRA, the precursor lesion of CRC in a sequence that may last 10–15 years (5), is common in older people, especially those over 50 years of age (6-8).

Many Asian countries, including China, have experienced an increase of two to four times in the incidence of CRC during the past few decades (9). CRC was ranked as the third most prevalent malignancy in Shanghai urban area (10,11). Data from the CancerBase of the international Agency for Research on Cancer (IARC) show that the incidence in many affluent Asian countries is similar to that in the west (9).

It is recognized that the combination of colonoscopy screening and polypectomy for CRA could reduce the incidence and mortality of CRC (3,8,12,13). However, the recurrence rate is high (14,15). Interest has recently been focused on the relationship between chemoprevention and recurrence of CRA. Several agents, including non-steroidal anti-inflammatory drugs such as aspirin and cyclooxygenase-2 (Cox-2) selective inhibitors such as celecoxib, have been shown to be effective for chemoprevention but have not gained general acceptance due to side effects (16,17).

Therefore, the use of nutritional compounds, which usually have fewer severe side effects, is an emerging field in CRA prevention and health maintenance.

The effectiveness of folic acid (FA) and its derivatives (folate) in the prevention of CRC and CRA recurrence has been investigated. However, clinical trials evaluating the chemopreventive effect of FA in humans have yielded conflicting results (18-22). However, these above studies do not provide information on primary prevention by
FA.

There has been little research on primary prevention of CRA, especially in China. Here, we report a randomized, controlled, large number, open-label cohort trial investigating the effect of supplementation with FA on CRA primary prevention in multiple centers, in patients aged over 50 years.

Methods

Design and setting

The trial had a prospective, randomized, controlled design comparing daily supplementation with 1 mg FA with controls (who did not receive FA). Patients were randomized after a run-in period to receive either 1 mg FA daily supplements or treatment without FA over 3 years. The trial involved five clinical centers (Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine; Military General Hospital of Beijing, PLA; Southwest Hospital, Third Military Medical University; Shanghai 1st Hospital, Shanghai Jiao-Tong University; and Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School). All participants were older than 50 years.

Study outcomes

Primary outcome

The primary outcome parameter was the incidence of any type of CRA (tubulovillous, tubular, villous or serrated lesions) at 3-year follow-up colonoscopy in both groups.
The occurrence, number, location, size and histological subtype of adenoma and invasive growth were assessed in both groups.

Secondary outcome

Plasma folate was evaluated as a secondary outcome parameter at the beginning and end of the follow-up period. Serum samples were stored at –20°C until needed. We used an automated chemiluminescence system (ACS: 180; Chiron Diagnostics Corporation, East Walpole, MA, USA) to determine FA concentrations in plasma. The relationship between initial plasma folate level and the incidence of CRA was determined as well as the effective therapeutic FA level.

Sample population, randomization and interventions

Recruitment was conducted between June, 2008, and May, 2012. A sample size of 800 participants was selected to provide power of at least 80% to detect a risk reduction with FA (40% reduction) using a two-sided statistical significance level of \( P < 0.05 \) (19). This assumed an adenoma occurrence rate of 30% in the control group (23,24) and a follow-up rate of 80%. Potential participants were identified by clinical center staff from colonoscopy and pathology reports. Eligible participants were aged 50–80 years and had undergone complete colonoscopy with no adenoma found at least twice in the past five years, the last colonoscopy being performed within one year before recruitment. Exclusion criteria for participation in the study were a history of hereditary non-polyposis colorectal cancer or familial adenomatous polyposis,
inflammatory bowel disease, colorectal cancer, malabsorption syndromes, any condition that could be worsened by supplemental FA, and any condition commonly treated with folate (e.g. arthritis, megaloblastic anemia, atrophic gastritis) or NSAIDs (e.g. rheumatoid arthritis, vasculitis, some connective tissue disorders).

After baseline colonoscopy and a run-in period, we used computer-generated randomization to allocate participants in a 1:1 ratio to 1 mg/d FA or treatment without FA (Multivitamin Tablets (6); Sino-American Shanghai Squibb Pharmaceutical Co., Ltd; a standard vitamin supplement containing no folate). The study start date was the first day of FA intake.

**Follow-up and study visits**

During the 3-year follow-up period, participants in the FA supplementation group were asked to visit their medical centers every 3 months to check for any adverse events or medication changes, and to confirm that they had been taking the study medication regularly. Participants in the control group were followed-up by telephone or letter at the same intervals. Data on health status and complaints about the FA supplement were collected and, after each visit, the study medication for the next study period was dispensed. The final visit, 3 years after the start of the study, included colonoscopy.

All colonoscopies had to have been performed by skilled endoscopists who were unaware of the clinical details (especially whether the subject was taking the FA supplement), using standard colonoscopes (CF 200L, 240L or 260L; Olympus®).
Optical Co., Ltd, Tokyo, Japan). Bowel preparation included 2–5 L polyethylene glycol electrolyte solution administered in the morning before an afternoon examination or the previous evening in patients undergoing examination in the morning. If the colonoscopy did not reach the cecum, it was not included for further analysis and the patient was required to undergo colonoscopy by another endoscopist on the next occasion. The mean colonoscope withdrawal time was required to be 6 minutes or more. During the examination, the location and size of all polypoid lesions were recorded. The size of each polyp was measured in vitro and all retrieved polypoid lesions were sent to local pathology laboratories for histologic evaluation. The results of the colonoscopy as well as histological confirmation were documented, as were clinical data on health status and complaints about and adherence to the study medication.

Plasma folate was evaluated at the end of the follow-up period to determine its relationship with the incidence of CRA and to ascertain adherence to treatment.

*Data management and statistical analysis*

Data collection was conducted using paper CRFs and the data were entered and stored in a validated database that conformed with GCP requirements. The CRFs were monitored regularly. The predefined primary statistical analysis was the chi-square test with a significance level of 5% comparing the risk of CRA between the two groups. The trial results were evaluated by intention-to-treat and per-protocol analysis. Risk ratios (RRs) and 95% confidence intervals (CIs) were also used compare the FA
supplementation and control groups by Cox regression methods.

Independent sample and paired t-tests were used for comparisons between the groups to evaluate the relationship between the initial plasma folate level and the incidence of CRA. All statistical analyses were performed using SPSS 17.0.

**Ethics**

The study was performed according to the study protocol, was approved by the ethics committee of each medical center and was registered with the Chinese Clinical Trial Registry (ChiCTR-PRC-08000123). Each participant was required to sign an informed consent form.

**Results**

**Participants and follow-up**

Nine-hundred and eighty participants who were confirmed to have no adenomas by colonoscopy entered the run-in period; after a two week run-in period, 860 underwent randomization for the study (Figure 1). Of the 120 participants who were not randomized, 25 (20.83%) were unable to avoid taking medication or supplements prohibited by the study, 20 (16.67%) were non-adherent and 46 (38.33%) declined to continue the study. Twenty-nine (24.17%) were excluded for other reasons (most were found to have a concurrent illness, such as dysfunction of the liver or kidney). Four-hundred and thirty participants were randomized to the 1 mg/d FA group and 430 to the control group. The first participant was enrolled in June, 2008 and the last
at the end of 2008. Seven hundred and ninety-one participants (91.98%) underwent colonoscopy after 3 years of follow-up. The remaining 69 participants were lost to follow-up ($n = 42$), discontinued the intervention ($n = 18$), or were unable to avoid regularly taking FA or NSAIDs for more than two weeks during the follow-up period ($n = 5$), and two in each group developed CRC. The mean time from randomization to completion of follow-up was $37.8 \pm 3.7$ months. There were no differences in baseline characteristics between the FA and the control groups (Table 1).

**Primary outcome measure**

After 3 years of follow-up, we found that FA supplementation may decrease the risk of CRA. In the intention-to-treat population, CRA occurred in 64 (14.88%) participants in the FA group and 132 (30.70%) in the control group (unadjusted RR, 0.49; 95% CI, 0.37–0.63; $P < 0.01$) (Table 2). Among the participants for whom follow-up information was available, three or more adenomas occurred in 14 (3.26%) participants in the FA group and 20 (4.65%) participants in the control group (unadjusted RR, 0.70; 95% CI, 0.36–1.77; $P = 0.38$). Adenoma occurred on the left side of the colon in 42 participants in FA group and 78 participants in the control group (9.77% vs. 18.14%); this was a significant difference (unadjusted RR, 0.54; 95% CI, 0.38–0.76; $P = 0.001$). However, there was no such trend in right-sided adenoma and the difference did not reach significance (16 participants in the FA group and 29 participants in the control group; unadjusted RR, 0.55; 95% CI, 0.30–1.00; $P = 0.07$).

We also evaluated the impact of FA on the occurrence of advanced CRA, which was
defined as an adenoma with a diameter of 10mm or more, a villous adenoma (≥ 25% villous) or an adenoma with high-grade dysplasia (23,24). Advanced CRA occurred in eight (1.86%) participants in the FA group and 22 (5.17%) participants in the control group, which was a significant difference (unadjusted RR, 0.36; 95% CI, 0.16–0.81; \( P = 0.01 \)). The results of the per-protocol analysis were similar to those of the intention-to-treat analysis. Adjustment for age, sex, clinical center and duration of follow-up at baseline did not substantially affect the results.

**Secondary outcome measures**

*Association of baseline plasma folate with adenoma risk*

We evaluated the relationship between plasma folate level and the occurrence of CRA. Baseline FA levels did not differ between the two groups, but did show a difference between participants who developed CRA and those who did not (Table 3). In the FA group, baseline FA was lower in participants who developed CRA (4.07 ± 2.73 ng/ml) than in those who had no adenoma (5.36 ± 3.94 ng/ml). The same tendency was found in the control group (4.28 ± 2.79 ng/ml vs. 5.85 ± 2.78 ng/ml). These results show that baseline plasma folate was inversely associated with CRA risk, which means that people with low plasma folate may be at high risk of CRA (\( P < 0.05 \) in FA group, \( P < 0.01 \) in control group).

*Effective therapeutic FA level and adenoma risk in participants with differing baseline plasma folate*
Although 1 mg/d FA supplements were provided to all participants randomized to the FA group, their plasma folate levels varied. As Table 3 shows, after 3 years of FA supplementation, plasma folate increased, especially in participants who did not develop adenoma (7.70 ± 3.06 ng/ml, \( P < 0.01 \)). However, although plasma folate was increased above baseline in the participants who had developed CRA by the end of the 3-year follow-up period, the difference was not significant (5.44 ± 2.19 ng/ml, \( P = 0.05 \)). These results indicate that there may be an effective therapeutic level of FA and that people who do not achieve this level may still be at risk of CRA.

To determine the therapeutic level of FA in subjects with differing baseline folate levels, we divided all of the participants who received FA supplements into two groups: those with low baseline plasma folate (< 4.27 ng/ml, the value was determined by ROC curve)(25) and those with high baseline plasma folate (≥ 4.27 ng/ml). The results are shown in Table 4. Most of the participants who received FA supplements exhibited a significant increase of plasma folate, but participants with high baseline plasma folate did not achieve an increase to a protective level. By contrast, some subjects achieved a protective level but CRA still occurred. This phenomenon indicates that there is a threshold level for effective therapeutic FA.

Plasma folate remained low (4.65 ± 1.75 ng/ml) after supplementation in the group in whom CRA occurred with low baseline levels. Doubling of FA (4.65/2.61) may not satisfy the requirements of these participants; FA may need to be elevated by more than three times (9.22/2.49) to avoid CRA.
Side effects and contraindications

Side effects are seldom reported for FA supplementation, especially with normal doses. In the present study, allergic reactions (one, 0.23%), gastrointestinal discomfort (four, 0.93%), diarrhea (one, 0.23%) and constipation (two, 0.47%) were reported. Similar rates were reported by those in the control group, who experienced gastrointestinal discomfort (three, 0.70%), diarrhea (one, 0.23%) and constipation (three, 0.70%) but no allergic reactions.

Discussion

The initiation and development of CRC is a complex process involving multiple molecular pathways; from the occurrence of adenoma to the development of carcinoma, the process can last two decades (5). Both aspirin and Cox-2 inhibitors can reduce the incidence of CRA and may have an effect on the development of CRC, but safe doses and durations of treatment remain to be determined and may limit their use in healthy individuals. Use of dietary agents that may delay the onset and progression of this disease is likely to have significant health benefits.

Folates are important cofactors in key DNA synthesis and methylation pathways (26). Many observational studies of folate and CRC in large populations have indicated that deficiency of dietary folate may be correlated with increased occurrence of CRC, but results differ between reports. We believe that carcinogenesis is a multistep process in which cancers arise as the result of interactions over time between genetic alterations and the environment, and that the timing of intervention may be of major importance.
However, there have been no systematic studies to evaluate the effect of folate on the primary prevention of CRA.

Our results show for the first time that 1mg FA supplements taken over a period of 3 years can decrease the risk of sporadic CRA in patients over 50 years of age. More importantly, FA supplements can significantly reduce the incidence of advanced CRA, which may reduce carcinogenesis. A similar trend was observed for left-sided adenomas, but not for right-sided or multiple (≥3) adenomas. Because FA plays an important role in DNA methylation and cellular homeostasis, folate deficiency might impair these processes and cause chromosomal breaks, as well as deleterious changes in gene expression. All of these factors might induce genomic instability and aberrant DNA methylation, which contribute to carcinogenesis (22,27,28). Data from our clinical trial clearly support a chemopreventive role for FA in primary prevention of CRA, especially in patients over 50 years of age. We believe that the mechanism of primary prevention of adenoma may differ from the effects of FA on progression from adenoma to carcinoma. Many preclinical carcinogenesis studies in animal models suggest that periods of tumor initiation and tumor progression or promotion are dissimilar (29). The timing of FA administration is important if it is to have a protective effect on normal mucosa in animals exposed to carcinogens or in mice bearing mutations in genes known to be involved in carcinogenesis (30). Our previous study demonstrated that FA supplementation was significantly associated with decreased risk of CRC in a mouse model, and that FA was more effective in a subgroup without precancerous lesions than in mice with precancerous lesions (31).
Thus, we suggest that, to reduce the incidence of CRC, it is better to provide FA before the initiation of CRA.

Our study shows that low plasma folate is associated with an increased risk of CRA, and FA supplementation at a dose of 1 mg/day can significantly reduce the adenoma risk. That means the baseline folate level might predict the risk of CRA, but this might be partly risk because it can be altered by further supplementation. We believe the effects of a chemopreventive agent, especially one based on a dietary component, may vary depending on the baseline state of sufficiency. Previous results showed that folate supplementation may protect against adenoma or cancer only in those with low baseline folate levels (32). Our data strongly support this theory; therefore, people with low plasma folate should be encouraged to take adequate folate supplements based on the potential perceived risk of CRC.

Interestingly and importantly, a threshold level for effective therapeutic FA may exist, which suggests that the degree plasma folate increase is more important than the dose of FA supplementation (Table 4). Our analysis demonstrates that primary prevention of CRA should be individualized. Participants with differing baseline plasma folate levels should be given FA supplementation at different doses or for different durations to achieve therapeutic levels. Subjects with high baseline folate will obtain limited benefit from FA supplements and only if their plasma folate is elevated significantly above baseline. However, subjects with low baseline folate should be encouraged to take FA supplements to achieve the therapeutic level. Those who achieve only limited increases of plasma folate may need higher doses or longer durations of
supplementation to reach the therapeutic level. The reason why there remained some in whom therapeutic levels were not achieved after 3 years of FA supplementation may be that the synthetic FA used in this study differs from natural folates in its chemopreventive properties, which may influence its absorption and utilization. Also, the participants in our study had a mean age of 60 years, and degeneration of gastrointestinal function with age may have led to malabsorption of FA. MTHFR polymorphisms, which may influence folate status, may also affect plasma folate levels; further studies are needed.

Nine (14.07%) participants in the FA group achieved therapeutic FA levels but developed CRA. Mean baseline plasma FA levels in these patients were quite high (7.15 ± 2.49 ng/ml) and three achieved effective increases of FA, which indicates that the mechanism of the development of CRA in these people was not principally due to low plasma folate. Other bioactive food components such as fiber, short-chain fatty acids, methionine or calcium might be involved. Further studies are needed.

Although several studies have suggested that high-dose FA might increase the recurrence and progression of CRC (33,34), only two participants in our FA group developed CRC during 3 years of follow-up and there was no significant difference with the control group. We believe that 1 mg/d FA supplementation is safe and has few side effects.

In our study, 14 participants developed multiple CRA in the FA group, most of whom (71.43%) did not reach therapeutic FA levels. A similar trend occurred in right-sided adenoma, so we hypothesize that higher doses and longer durations of FA
supplementation may significantly reduce the incidence of multiple CRA or right-sided adenoma. FA supplementation is relatively safe, and further studies of higher doses may be needed.

The overall average level of plasma folate in the present study seems lower than that reported in previous studies (18,19). We believe this may be due to the participants in our study being older (>50 years). B vitamin status is frequently inadequate in the elderly (35), and studies have shown that the elderly should be a particular concern because of age-related declines in vitamin absorption and extraction of vitamin B12 from protein (36), which may lead to subclinical folate deficiency (37). Ethnic differences should also be considered. Studies of genetic polymorphisms in folate metabolism suggest a causal role for folate in cancer prevention. The availability of 5-methyltetrahydrofolate (5-methylTHF), the main folate coenzyme in the circulation, is modified by a common single nucleotide polymorphism, 677C→T, in the MTHFR gene (38). The presence of this mutation is known to correlate with suboptimal folate status (39) and its prevalence has been shown to vary between populations (40). A recent study showed that genetic variations in exons of the FR-α gene, FOLR1, can cause severe folate deficiency in Eurasians (41). These gene mutations may cause the average level of plasma folate to be lower than those observed in previous studies.

Further studies are needed.

Our results show that about 30.70% of participants in the control group had developed CRA after 3 years; this incidence was quite high. We believe there may several reasons. First, previous studies have shown that the incidence of CRA is high in
elderly people (7,8,13,42), and the incidence of neoplastic lesions can reach 37.5% in asymptomatic patients (8). It is worth noting that, after the follow-up period, the incidence of CRA can reach 16–26% in patients with no adenomas on baseline screening, especially in those with hyperplastic polyps (43-45). The enrolled patients in our study were over 50 years old, which may have increased the incidence of CRA. Second, optimal bowel preparation as well as ongoing efforts to improve the technology of colonoscopy, such as the use of high definition endoscopy, could minimize the risk of missing important lesions in clinical practice. The endoscopists’ skill may also have contributed to our findings. According to experts, 6 minutes is the minimum time required for adequate inspection during instrument withdrawal (46), and this requirement may ensure the validity of CRA detection.

Because this was a clinical study, we cannot exclude the possibility of residual confounding, though we tried to avoid this; participants who were unable to avoid taking medication prohibited by the study (e.g. NSAIDs for more than two weeks during follow-up) were required to quit the study. We could not restrict the participants’ diets, but no folate fortified foods are currently available for purchase in China. Also, baseline folate levels showed no difference between the groups, and it is well known that the elderly seldom change their eating habits or food preferences, which may have minimized the influence of these factors.

Our study is the first to explore the relationship between folate intake and primary prevention of CRA in a Chinese population. The data were gathered from multiple centers, thereby lessening the potential for observation bias and measurement errors.
Despite these strengths, however, the study also had some limitations. For example, there is the possibility of differential recall between cases and controls. Furthermore, this was an open-label cohort study that did not contain a blank placebo group and did not use double-blind methods. However, the endoscopists were unaware of the clinical details (especially whether the subject was taking the FA supplement), which may have ensured the objectivity of the findings. Third, the FA level of most of the subjects enrolled in our study seems to be lower than that recorded in other studies (18,19), which suggests that those with lower folate levels may benefit from FA supplements. Because the enrolled patients in our study were Chinese, we still lack of the material about the effectiveness of FA supplementation in the non-Chinese population. Therefore, to popularize the usage of FA supplementation may still need more evidences. We should enlarge our sample size in further studies, especially including different ethnic population and those with higher basal folate levels to evaluate the impact of FA supplementation without observation bias. Lastly, we only provide a simple stratified results, which may have limited the power of the study.

In conclusion, we found a statistically significant relationship between FA supplementation and reduced risk of CRA in those over 50 years of age with no previous adenomas. Primary prevention with 1 mg/d FA reduced the incidence of CRA (RR, 0.485), especially advanced CRA and left-sided adenoma. People with differing baseline plasma folate levels should be given individualized treatment. Those with low plasma folate should be encouraged to take adequate supplements, and plasma folate should be elevated to an effective therapeutic level, which may
reduce the incidence of CRA.

Acknowledgement:

The authors wish to thank the Program for Innovative Research Team of Shanghai Municipal Education Commission for help in patient recruitment and record keeping. This work was supported by the grants from the National Science Found of China (30830055) and the Ministry of Public Health, China (No. 200802094).

The Corresponding Author has the right to grant on behalf of all authors. All authors of this manuscript have read and approved the final manuscript, and declared no conflict of interest.

Authorship Statement:

Guarantor of the article: Jing-Yuan Fang

Specific author contributions:

Qin-Yan Gao, Hui-Min Chen, Ying-Xuan Chen, Jie-Ting Tang, Zheng-Hua Wang (study concept and design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content)

Zhi-Zheng Ge, Xiao-Yu Chen, Ying-Chao Wang (technical and material support)

Jian-Qiu Sheng, Dian-Chun Fang, Cheng-Gong Yu, Ping Zheng (acquisition of data)

Jing-Yuan Fang (study concept and design; study supervision)

All authors approved the final version of the manuscript.
References:


9. Sung JJ, Lau JY, Goh KL, Leung WK; Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for


intake and the risk of colorectal cancer: a systematic review and meta-analysis.
Cancer Epidemiol 2011;35:2-10.


33. Kim YI. Role of folate in colon cancer development and progression. J Nutr 2003;133:3731S-3739S.


35. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and


Figure Legends

Figure 1. Flow diagram of the phases of the study.
Figure 1

980 individuals (>50 yrs) no adenoma confirmed by colonoscopy entered Run-in Period

120 Excluded
1) Unable to avoid taking medication or supplements prohibited by the study (n=25)
2) Declined to continue the study (n=46)
3) Nonadherent (n=20)
4) Excluded for other reasons (n=29)

Randomization (n=860)

Allocated to folic acid group (n=430)
Received FA 1mg/day

Allocated to control group (n=430)
Received vitamins without FA

Assessed after 3 years

Lost to follow-up (n=23)
Unable to avoid taking FA or NSAIDs (n=3)
Discontinued intervention (n=18)
Developed to CRC (n=2)

384 Completed Second Follow-up Examination

Lost to follow-up (n=19)
Unable to avoid taking FA or NSAIDs (n=2)
Developed to CRC (n=2)

447 Completed Second Follow-up Examination
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Folic Acid Group (n=430)</th>
<th>Control Group (n=430)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (±SD, years)</td>
<td>60.79±7.53</td>
<td>60.26±7.11</td>
<td>0.92</td>
</tr>
<tr>
<td>Male (%)</td>
<td>50.92%</td>
<td>49.75%</td>
<td>0.85</td>
</tr>
<tr>
<td>Plasma folate (ng/ml)</td>
<td>5.04</td>
<td>5.56</td>
<td>0.09</td>
</tr>
<tr>
<td>Cigarette smoke (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>19.3%</td>
<td>15.35%</td>
<td>0.15</td>
</tr>
<tr>
<td>Ex smoker</td>
<td>2.79%</td>
<td>1.86%</td>
<td>0.49</td>
</tr>
<tr>
<td>Alcohol consumption (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>17.44%</td>
<td>14.88%</td>
<td>0.35</td>
</tr>
<tr>
<td>Weekends only</td>
<td>8.37%</td>
<td>11.16%</td>
<td>0.21</td>
</tr>
<tr>
<td>Tea consumption (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.86%</td>
<td></td>
<td>8.6%</td>
<td>0.14</td>
</tr>
<tr>
<td>Coffee consumption (%)</td>
<td>3.72%</td>
<td>5.81%</td>
<td>0.20</td>
</tr>
<tr>
<td>Grain/cereals (±SD, g/day)</td>
<td>352.1±8.7</td>
<td>361.7±10.6</td>
<td>0.75</td>
</tr>
<tr>
<td>Meat (±SD, g/day)</td>
<td>55.6±3.1</td>
<td>59.3±2.8</td>
<td>0.29</td>
</tr>
<tr>
<td>Fish (±SD, g/day)</td>
<td>104.7±4.0</td>
<td>110.4±3.1</td>
<td>0.26</td>
</tr>
<tr>
<td>Citrus fruit (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Usually</td>
<td>33.02%</td>
<td>39.3%</td>
<td>0.07</td>
</tr>
<tr>
<td>Seldom</td>
<td>2.56%</td>
<td>1.86%</td>
<td>0.64</td>
</tr>
<tr>
<td>Milk (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Usually</td>
<td>53.72%</td>
<td>48.14%</td>
<td>0.12</td>
</tr>
<tr>
<td>Seldom</td>
<td>7.21%</td>
<td>6.51%</td>
<td>0.68</td>
</tr>
<tr>
<td>Leaf green vegetables (±SD, g/day)</td>
<td>85.7±3.2</td>
<td>79.5±4.9</td>
<td>0.53</td>
</tr>
<tr>
<td>Other vegetables (±SD, g/day)</td>
<td>143.2±4.7</td>
<td>135.6±6.0</td>
<td>0.31</td>
</tr>
<tr>
<td>Soybean products (±SD, g/day)</td>
<td>113.5±4.1</td>
<td>110.7±5.4</td>
<td>0.68</td>
</tr>
</tbody>
</table>
Table 2. Risk of adenoma after randomization in the intention-to-treat population

<table>
<thead>
<tr>
<th></th>
<th>Folic Acid (n=430)</th>
<th>Control (n=430)</th>
<th>Relative Risk (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any adenoma</td>
<td>64 (14.88%)</td>
<td>132 (30.70%)</td>
<td>0.49 (0.37-0.63)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No. of adenomas ≥3</td>
<td>14 (3.26%)</td>
<td>20 (4.65%)</td>
<td>0.70 (0.36-1.77)</td>
<td>0.38</td>
</tr>
<tr>
<td>Left-sided adenoma</td>
<td>42 (9.77%)</td>
<td>78 (18.14%)</td>
<td>0.54 (0.38-0.76)</td>
<td>0.001</td>
</tr>
<tr>
<td>Right-sided adenoma</td>
<td>16 (3.72%)</td>
<td>29 (6.74%)</td>
<td>0.55 (0.30-1.00)</td>
<td>0.07</td>
</tr>
<tr>
<td>Advanced adenoma</td>
<td>8 (1.86%)</td>
<td>22 (5.17%)</td>
<td>0.36 (0.16-0.81)</td>
<td>0.01</td>
</tr>
<tr>
<td>CRC</td>
<td>2 (0.47%)</td>
<td>2 (0.47%)</td>
<td>1.00 (0.14-7.07)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; RR, risk ratio; CRC, colorectal cancer

The intention-to-treat population comprised all randomized participants with 3 years of follow-up data, including those participants who discontinued. P values are based on the chi-square test.

*Adjustment for age, sex, clinical center and duration of follow-up at baseline.
Table 3. Plasma folate before and after follow-up

<table>
<thead>
<tr>
<th></th>
<th>FA group (ng/ml)</th>
<th>Control group (ng/ml)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>CRA</td>
<td>P</td>
<td>No</td>
</tr>
<tr>
<td>CRA occurred</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma folate in baseline</td>
<td>5.36±3.94</td>
<td>4.07±2.73</td>
<td>&lt;0.05</td>
<td>5.85±2.78</td>
</tr>
<tr>
<td>Plasma folate after follow-up</td>
<td>7.70±3.06</td>
<td>5.44±2.19</td>
<td></td>
<td>5.90±2.18</td>
</tr>
<tr>
<td>P</td>
<td>&lt;0.01</td>
<td>0.05</td>
<td></td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

All data were shown in the form of : mean±SD.
### Table 4. The benefit of FA supplementation and adenoma risk in participants with differing baseline plasma folate levels (n=384)

<table>
<thead>
<tr>
<th></th>
<th>Baseline plasma folate*</th>
<th>Baseline plasma folate</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(&lt;4.27ng/ml)</td>
<td>(≥4.27ng/ml)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>118</td>
<td>266</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No CRA</td>
<td>(n=76)</td>
<td>CRA occurred</td>
<td>No CRA</td>
<td>CRA occurred</td>
</tr>
<tr>
<td>n</td>
<td>(n=244)</td>
<td>(n=22)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma folate in baseline</td>
<td>2.49±1.51</td>
<td>2.61±1.34</td>
<td>7.07±3.78</td>
<td>6.08±2.57</td>
</tr>
<tr>
<td>Plasma folate after follow-up</td>
<td>9.22±2.96</td>
<td>4.65±1.75</td>
<td>8.14±3.10</td>
<td>6.86±2.24</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.01</td>
<td>0.85</td>
</tr>
</tbody>
</table>

All data were shown in the form of: mean±SD

n: number of participants

* RR,6.13; 95%CI, 3.44-10.91, which means participants with low baseline plasma folate may had a high risk of CRA.
Folic acid prevents the initial occurrence of sporadic colorectal adenoma in Chinese over 50 years of age: a randomized clinical trial

Jing-Yuan Fang, Qin-Yan Gao, Hui-min Chen, et al.

Cancer Prev Res Published OnlineFirst May 16, 2013.